SG10201803778PA - Treatment for rheumatoid arthritis - Google Patents
Treatment for rheumatoid arthritisInfo
- Publication number
- SG10201803778PA SG10201803778PA SG10201803778PA SG10201803778PA SG10201803778PA SG 10201803778P A SG10201803778P A SG 10201803778PA SG 10201803778P A SG10201803778P A SG 10201803778PA SG 10201803778P A SG10201803778P A SG 10201803778PA SG 10201803778P A SG10201803778P A SG 10201803778PA
- Authority
- SG
- Singapore
- Prior art keywords
- rheumatoid arthritis
- treatment
- csf antibodies
- mor103
- dosages
- Prior art date
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title abstract 4
- 230000009286 beneficial effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12185235 | 2012-09-20 | ||
| US201261703871P | 2012-09-21 | 2012-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201803778PA true SG10201803778PA (en) | 2018-06-28 |
Family
ID=46963526
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201803778PA SG10201803778PA (en) | 2012-09-20 | 2013-09-19 | Treatment for rheumatoid arthritis |
| SG11201501595YA SG11201501595YA (en) | 2012-09-20 | 2013-09-19 | Treatment for rheumatoid arthritis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201501595YA SG11201501595YA (en) | 2012-09-20 | 2013-09-19 | Treatment for rheumatoid arthritis |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20150246969A1 (ja) |
| EP (3) | EP2897977A1 (ja) |
| JP (3) | JP2015533806A (ja) |
| KR (3) | KR20220028177A (ja) |
| CN (2) | CN104995210A (ja) |
| AU (2) | AU2013320261A1 (ja) |
| BR (1) | BR112015006189B1 (ja) |
| CA (1) | CA2884124A1 (ja) |
| CL (2) | CL2015000696A1 (ja) |
| CR (1) | CR20150153A (ja) |
| DO (1) | DOP2015000070A (ja) |
| EA (1) | EA031489B1 (ja) |
| HK (1) | HK1208231A1 (ja) |
| IL (1) | IL237554B (ja) |
| IN (1) | IN2015KN00657A (ja) |
| MA (1) | MA37946B1 (ja) |
| MX (2) | MX2015003644A (ja) |
| MY (1) | MY175388A (ja) |
| PE (1) | PE20151079A1 (ja) |
| PH (1) | PH12015500591B1 (ja) |
| SG (2) | SG10201803778PA (ja) |
| UA (1) | UA117228C2 (ja) |
| WO (1) | WO2014044768A1 (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2015KN00657A (ja) * | 2012-09-20 | 2015-07-17 | Morphosys Ag | |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res (Munich) Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| US9833410B2 (en) | 2012-10-31 | 2017-12-05 | Takeda Gmbh | Lyophilized formulation comprising GM-CSF neutralizing compound |
| CA2922251C (en) | 2013-08-30 | 2023-10-17 | Takeda Gmbh | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics |
| US11299528B2 (en) * | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| EP3139960B1 (en) * | 2014-05-07 | 2024-01-17 | Takeda Pharmaceutical Company Limited | Liquid formulation comprising gm-csf neutralizing compound |
| GB201519331D0 (en) * | 2015-11-02 | 2015-12-16 | Glaxosmithkline Ip Dev Ltd | Treatment paradigm |
| CN108601819B (zh) | 2015-12-17 | 2022-03-15 | 约翰霍普金斯大学 | 用死亡受体激动剂改善系统性硬化症 |
| KR102508650B1 (ko) | 2016-04-07 | 2023-03-13 | 더 존스 홉킨스 유니버시티 | 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법 |
| KR101953706B1 (ko) | 2016-09-19 | 2019-03-05 | 아이-맵 | 항-gm-csf 항체 및 이것의 사용 |
| EP3623382A1 (en) | 2018-09-14 | 2020-03-18 | Universität Zürich | Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct |
| US11655293B2 (en) * | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
| WO2021204649A1 (en) | 2020-04-06 | 2021-10-14 | Glaxosmithkline Intellectual Property Development Limited | Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| CN1142940C (zh) | 1996-10-04 | 2004-03-24 | 安姆根有限公司 | 含有mpl配体的药物组合物 |
| US7455836B2 (en) | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| DK1888643T3 (en) * | 2005-05-18 | 2015-01-05 | Morphosys Ag | Anti-GM-CSF antibodies as well as their uses |
| EP1916997B1 (en) | 2005-08-05 | 2018-04-18 | Amgen Inc. | Stable aqueous protein pharmaceutical formulations and their preparation |
| EP2010214A4 (en) * | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
| US8093360B2 (en) * | 2006-09-28 | 2012-01-10 | Elusys Therapeutics, Inc. | Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use |
| EP2402013A1 (en) * | 2006-11-21 | 2012-01-04 | Kalobios Pharmaceuticals, Inc. | Methods of Treating Chronic Inflammatory Diseases using a GM-CSF Antagonist |
| AU2008232902B2 (en) * | 2007-03-30 | 2013-10-03 | Medlmmune, Llc | Antibody formulation |
| EP2137325A1 (en) * | 2007-04-02 | 2009-12-30 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
| AU2008235044B2 (en) | 2007-04-05 | 2011-08-25 | Sandoz Ag | Stable aqueous G-CSF formulations |
| US20090004189A1 (en) * | 2007-06-18 | 2009-01-01 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| BRPI0820530A2 (pt) | 2007-11-13 | 2015-06-16 | Boehringer Ingelheim Int | Anticorpos monoclonais que se ligam ao hgm-csf e composições medicinais compreendendo os mesmos |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| BRPI0918103A2 (pt) * | 2008-12-22 | 2016-07-05 | Univ Melbourne | "método para o tratamento da dor em um indivíduo" |
| CA2746827C (en) | 2008-12-22 | 2018-01-23 | The University Of Melbourne | Osteoarthritis treatment |
| JP2010241718A (ja) | 2009-04-03 | 2010-10-28 | Kyowa Hakko Kirin Co Ltd | 安定な抗体の水溶液製剤 |
| CN102439039A (zh) * | 2009-05-05 | 2012-05-02 | 莫佛塞斯公司 | 多发性硬化的治疗 |
| SI2341061T1 (sl) | 2009-12-31 | 2013-12-31 | Arven Ilac Sanayi Ve Ticaret A.S. | Nov postopek za pripravo G-CSF-ja (granulocitne kolonije stimulirajočega faktorja) |
| WO2011109365A2 (en) * | 2010-03-01 | 2011-09-09 | Progenics Pharmaceuticals, Inc. | Concentrated protein formulations and uses thereof |
| BR112013033944A2 (pt) | 2011-07-06 | 2017-12-19 | Morphosys Ag | combinação sinérgica |
| IN2015KN00657A (ja) * | 2012-09-20 | 2015-07-17 | Morphosys Ag |
-
2013
- 2013-09-19 IN IN657KON2015 patent/IN2015KN00657A/en unknown
- 2013-09-19 BR BR112015006189-3A patent/BR112015006189B1/pt active IP Right Grant
- 2013-09-19 WO PCT/EP2013/069501 patent/WO2014044768A1/en active Application Filing
- 2013-09-19 CN CN201380049042.8A patent/CN104995210A/zh active Pending
- 2013-09-19 US US14/429,996 patent/US20150246969A1/en not_active Abandoned
- 2013-09-19 CA CA2884124A patent/CA2884124A1/en active Pending
- 2013-09-19 KR KR1020227006147A patent/KR20220028177A/ko not_active Application Discontinuation
- 2013-09-19 KR KR1020237008704A patent/KR20230041086A/ko not_active Application Discontinuation
- 2013-09-19 EP EP13763100.8A patent/EP2897977A1/en not_active Withdrawn
- 2013-09-19 EA EA201590359A patent/EA031489B1/ru unknown
- 2013-09-19 SG SG10201803778PA patent/SG10201803778PA/en unknown
- 2013-09-19 SG SG11201501595YA patent/SG11201501595YA/en unknown
- 2013-09-19 EP EP21169696.8A patent/EP3916013A1/en active Pending
- 2013-09-19 EP EP18155371.0A patent/EP3345923A1/en not_active Withdrawn
- 2013-09-19 UA UAA201502131A patent/UA117228C2/uk unknown
- 2013-09-19 MA MA37946A patent/MA37946B1/fr unknown
- 2013-09-19 MX MX2015003644A patent/MX2015003644A/es unknown
- 2013-09-19 MY MYPI2015700862A patent/MY175388A/en unknown
- 2013-09-19 KR KR1020157009911A patent/KR20150056846A/ko active Application Filing
- 2013-09-19 CN CN201811553113.9A patent/CN109999195A/zh active Pending
- 2013-09-19 AU AU2013320261A patent/AU2013320261A1/en not_active Abandoned
- 2013-09-19 JP JP2015532412A patent/JP2015533806A/ja active Pending
- 2013-09-19 PE PE2015000350A patent/PE20151079A1/es unknown
-
2015
- 2015-03-04 IL IL237554A patent/IL237554B/en active IP Right Grant
- 2015-03-18 PH PH12015500591A patent/PH12015500591B1/en unknown
- 2015-03-19 CL CL2015000696A patent/CL2015000696A1/es unknown
- 2015-03-20 CR CR20150153A patent/CR20150153A/es unknown
- 2015-03-20 DO DO2015000070A patent/DOP2015000070A/es unknown
- 2015-03-20 MX MX2021006111A patent/MX2021006111A/es unknown
- 2015-09-09 HK HK15108769.5A patent/HK1208231A1/xx unknown
-
2016
- 2016-10-26 AU AU2016250388A patent/AU2016250388B2/en active Active
-
2018
- 2018-01-26 US US15/880,726 patent/US10913792B2/en active Active
- 2018-03-28 JP JP2018061614A patent/JP2018138551A/ja active Pending
- 2018-04-12 CL CL2018000933A patent/CL2018000933A1/es unknown
-
2021
- 2021-01-08 US US17/144,685 patent/US20210130451A1/en active Pending
-
2022
- 2022-08-25 JP JP2022133957A patent/JP2022169709A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201803778PA (en) | Treatment for rheumatoid arthritis | |
| MX2013009679A (es) | Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso. | |
| UA113403C2 (xx) | Спосіб підвищення ефективності folr1 терапії раку | |
| MX2020010693A (es) | Uso de peptidos glp-1 de accion prolongada. | |
| NZ630542A (en) | Methods of treating a tauopathy | |
| NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
| UA112288C2 (uk) | Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими | |
| MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
| MX367341B (es) | Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades. | |
| SG194701A1 (en) | Anti-cd40 antibodies and methods of use | |
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| MX2017003216A (es) | Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. | |
| PH12014501985B1 (en) | Il-17 antibody formulation | |
| MX356317B (es) | Tratamiento de síntomas asociados a gastroparesia femenina. | |
| PH12017500270A1 (en) | Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain | |
| MD4615C1 (ro) | Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine | |
| MX2013003168A (es) | Anticuerpo contra ephrin b2 y su uso. | |
| MX2016011706A (es) | Formulaciones de progesterona. | |
| MX2019008148A (es) | Uso de peptidos glp-1 de accion prolongada. | |
| TN2013000265A1 (en) | Anti-cd38 antibodies | |
| TN2013000068A1 (en) | Anti-vegfr-3 antibody compositions | |
| UA72268U (ru) | Способ лечения когнитивных нарушений с помощью комплекса низкомолекулярных полипептидных фракций (препарат "кортексин") | |
| UA74882U (uk) | Фармацевтична композиція для лікування сексуальної дисфункції | |
| UA97054C2 (ru) | Способ комплексного лечения больных с зависимостью вследствие употребления психоактивных веществ | |
| UA69880U (ru) | Способ премедикации у онкологических больных |